Viemed Healthcare, Inc. · NASDAQ:VMD
Viemed Healthcare — Investor Presentation (August 2023)
25 slides from Viemed Healthcare's investor presentation, Aug 10, 2023
Slide 1: Investor Presentation: Leading the Healthcare Industry in Home Respiratory Care
Investor Presentation Leading the Healthcare Industry in Home Respiratory Care NASDAQ: VMD TSX: VMD.TO August 2023
Slide 2: Disclaimers and Other Important Information
DISCLAIMERS Disclaimers and Other Important Information This presentation (the “Presentation”) about Viemed Healthcare, Inc. (“Viemed”) is dated as of August 2023. It is information in a summary form and does not purport to be complete. The data contained herein is derived from various internal and
Slide 3: Viemed at a Glance
▪ Largest independent specialized provider of non-invasive ventilation (NIV) in the US home respiratory health care industry ▪ Highly profitable with a ~30% CAGR in revenue growth since spinout in 2017 ▪ Service offering includes 24x7 in home respiratory care including specialized respiratory therap
Slide 4: Our Journey
SLEEP MANAGEMENT FOUNDED Annual Revenues: $0.24M USD Respiratory DME specializing in CPAPS & Oxygen HSD Annual Revenues: $3.58M USD Home Sleep Delivered – Specializing in home sleep tests VENTILATOR EXPANSION Annual Revenues: $4.60M USD Non Invasive ventilator introduced to market PHM ACQUISITION An
Slide 5: Key Investment Consideration
Key Investment Consideration Specialized US based respiratory healthcare services company ▪ Focused on Chronic Obstructive Pulmonary Disease (COPD) and growing aging population ▪ $50 billion of annual healthcare cost in the U.S. spent on COPD Significant Market Growth Opportunity ▪ 10,000 baby boome
Slide 6: Current State of the Industry
Viemed Healthcare, Inc. | Investor Presentation Current State of the Industry The Medicare population is growing Expenditures are expected to grow at a 5.5% CAGR from $67.1 billion in 2021 to $114.5 billion in 2031 5.5% CAGR At the age of 65, patients qualify for Medicare Historical and Projected US
Slide 7: NIV Market Penetration
NIV Market Penetration 25 Million (estimated) people in the U.S. have COPD 2,500,000 or 10% have stage 4 COPD 1,250,000 or 50% of those with stage 4 COPD develop chronic respiratory failure becoming candidates for our therapy Approximately 80,000 annual Medicare beneficiaries on NIV service * Viemed
Slide 8: Services and Payors
Services and Payors Viemed Healthcare, Inc. | Investor Presentation Ventilation 60% Sleep 17% Oxygen 10% Other 13% Medicare 45% Medicaid 9% Commercial 28% MA/MCO 11% Private 7% SERVICE MIX 2nd Quarter 2023 PAYOR MIX 2nd Quarter 2023 Slide 8
Slide 9: The Viemed Solution
The Viemed Solution Registered Respiratory Therapists (RTs) assigned to each patient and on call 24X7 ▪ All RTs are COPD educators ▪ Assess and service medical equipment ▪ Overseen by pulmonologists on staff ▪ Behavioral health specialist support Each patient is given a customized in-home care plan
Slide 10: A Dedicated 24/7 Respiratory Therapist with all our Viemed products
A DEDICATED 24/7 RESPIRATORY THERAPIST with all our Viemed products Ventilators Sleep Therapy Oxygen Therapy Patient Engagement Percussion Vests Slide 10
Slide 11: Proven Organic Growth Strategy
Proven Organic Growth Strategy Location selection ▪ Based on high COPD rates ▪ Target hospitals and facilities with high readmission rates and near existing service area ▪ Leverage existing relationships and operate heavily in rural markets Unique lean deployment model ▪ No costly retail stores ▪ Sa
Slide 12: Complementary Acquisition Initiatives
Complementary Acquisition Initiatives Viemed Healthcare, Inc. | Investor Presentation Acquisition of Tennessee-based Home Medical Products, Inc. (HMP) providing geographic, product, and payor diversification, completed June 1, 2023 ▪ Operations in Tennessee, northern Alabama, & northern Mississippi
Slide 13: Published Research: Real-world results
Published Research Real-world results Viemed Healthcare, Inc. | Investor Presentation 43% Relative mortality reduction if utilized within 0 - 7 days 11.6% Cost reduction if utilized within 0 – 7 days 7.2% Cost reduction if utilized within 0 – 15 days $5,484 Cost reduction if utilized within 0-7 days
Slide 14: Technology and Remote Care
Technology and Remote Care ▪ Mission of becoming a leading healthcare technology company coupled with high touch human interaction in the home ▪ Goal is to improve quality of life and length of time patients spend with loved ones ▪ Increase efficiency of clinicians through improved remote workflow a
Slide 15: Objectives for the Next Months
Objectives for the Next 24 Months ▪ Grow active patient base while entering new target markets through geographic expansion ▪ Communicate findings from the growing number of research studies to referral sources and payors in order to save more lives and increase market penetration ▪ Diversify payor
Slide 16: Viemed Financial
VieMed Financial meyune | INformation
Slide 17: Regulatory Update
Regulatory Update ▪ CMS has made improvements in the process of patients obtaining quality care (i.e. telehealth rules, relaxing face to face requirements, remote patient monitoring, etc.) ▪ Non-invasive vents removed from 2021 competitive bidding program (3 year term) and competitive bidding progra
Slide 18: Vent Revenue Model
Vent Revenue Model ▪ Monthly rental fee – reimbursed by insurance and covered by Medicare ▪ Uncapped rental contract for ventilators (60 % of 2Q23 revenue) ▪ Average monthly vent reimbursement of ~US$1,050 ▪ Pricing includes equipment rental, RT service, supplies and maintenance of equipment ▪ Other
Slide 19: Historical Financial Performance
0 2,000 4,000 6,000 8,000 10,000 Viemed Healthcare, Inc. | Investor Presentation Historical Financial Performance Active Vent Rental Patients 10,005 as of 6/30/23 $140,000,000 $120,000,000 $110,000,000 $100,000,000 $80,000,000 $60,000,000 $40,000,000 $20,000,000 $0 2019 2020(1) 2021(2) 2022(3) $131.
Slide 20: Capital Markets Profile
Capital Markets Profile Viemed Healthcare, Inc. | Investor Presentation 38,400,422 & 40,753,124 Shares outstanding & fully diluted $10.2M 20% Insider beneficial ownership Cash on hand in USD Total LT debt in USD $12M Total staff 993 Market cap as of June 30, 2023: ~$325M (USD) Stock price as of June
Slide 21: Corporate Structure
Viemed Healthcare, Inc. | Investor Presentation Corporate Structure Viemed Healthcare Inc. (Canadian Parent Company Listed on NASDAQ & TSX) Viemed Inc. (Delaware Corporation/US Subsidiary) Home Sleep Delivered, LLC (US Sub- Louisiana) Viemed Clinical Services, LLC (US Sub- Louisiana) Viemed Healthca
Slide 22: Board of Directors
Board of Directors Viemed Healthcare, Inc. | Investor Presentation Casey Hoyt Chief Executive Officer and Director Randy Dobbs Chairman of the Board and Independent Director Todd Zehnder Chief Operating Officer and Director Nitin Kaushal Independent Director Bruce Greenstein Independent Director Tim
Slide 23: Investor Relations
Investor Relations: Glen Akselrod Bristol Capital IR glen@bristolir.com Tel: 905 326 1888 Slide 23
Slide 24: Viemed Appendix
Viemed Appendix
Slide 25: Reconciliation of Net Revenue and Adjusted EBITDA
Viemed Healthcare, Inc. | Investor Presentation 2019 2020 2021 2022 1H 2023 Reconciliation of Net Revenue(1) Revenue 80.3$ 131.3$ 117.1$ 138.8$ 82.9$ Bad Debt Expense - - - - - Net Revenue 80.3$ 131.3$ 117.1$ 138.8$ 82.9$ Reconciliation of Adjusted EBITDA(2) Net Income 8.5$ 31.5$ 9.1$ 6.2$ 3.8$ Depr
Viemed Healthcare — Investor Presentation (August 2023) on 6ix